Navigation Links
MDS Responds to AECL and Government of Canada Announcements Regarding Maple Project
Date:5/16/2008

TORONTO, May 16 /PRNewswire-FirstCall/ - Earlier this morning, Atomic Energy of Canada Ltd. (AECL) announced it would discontinue the development of the MAPLE reactors at Chalk River, but remains committed to providing ongoing supply of medical isotopes.

MDS Inc., a leading provider of products and services to the global life sciences markets, was not consulted by AECL about this decision, and the company is evaluating these developments. MDS Nordion, a business unit of MDS, is a leading provider of medical isotopes and radiopharmaceuticals.

"The most important issue has always been the continuity of medical isotope supply for patients worldwide," said Stephen P. DeFalco, President and CEO, MDS Inc. "We are pleased that the government has asked AECL to pursue the extension of the NRU operation beyond its current license and to ensure the ongoing supply of these critical medical isotopes."

MDS is disappointed that AECL has stated it will not complete the MAPLE project despite significant investment and effort over the past 12 years. The company will evaluate all options and pursue appropriate steps to protect the interests of patients, its customers and its shareholders.

About MDS

MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services that our customers need for the development of drugs and the diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 5,500 highly skilled people in 29 countries. Find out more at http://www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.


'/>"/>
SOURCE MDS Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Undeterred Despite the Obstacles: American Refugee Committee Responds to Tragedy in Myanmar
2. Aid Urgently Needed in Myanmar (Burma): Lutheran World Relief Responds
3. Neuralstem Responds to Incorrect StemCells, Inc. Release on Patents
4. Terumo Cardiovascular Systems Responds to Allegations of Patent Infringement
5. The Toy Industry Association Responds to Washington State Law Governing the Sale of Toys and the Governors Veto of Key Sections of the Bill
6. Biotest Pharmaceuticals Corporation Responds to Orphan Drug Act Announcement
7. DRAXIS Responds to Trading
8. Maternal love: How a mothers brain responds to her infant
9. DuPont Responds to Spelter, W.Va. Lawsuit Rulings
10. Blue Cross of California Responds to Recent Media Coverage of Rescission
11. Veterans for Americas (VFA) Wounded Warrior Outreach Program Responds to Fort Drum in Aftermath of Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... (HLA), the nation's first interactive health literacy software tool, and the Cancer Patient ... aspects of cancer patient education, today announce a new strategic alliance. , ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
(Date:9/19/2017)... medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound energy ... ... Jim Bertolina, PhD ... Tom Tefft ... executive Josh Stopek , PhD, who has led R&D and business development teams at ...
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
Breaking Medicine Technology: